Compare State Street PDR S&P Retail ETF (XRT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street PDR S&P Retail ETF vs Zoetis Inc — how do they compare? State Street PDR S&P Retail ETF trades at $88.84, while Zoetis Inc trades at $72.57 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while State Street PDR S&P Retail ETF pays none, and State Street PDR S&P Retail ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| XRT | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $92.35 | $156.76 |
52-Week Low | $77.28 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XRT trades at $88.81, down 1.96% today, with a bullish technical signal from moving averages and key indicators like ADX suggesting a strong trend. The ETF's valuation metrics are not available in the provided data, but recent news highlights retail sector focus amid mixed economic signals. A dividend of $0.19 is scheduled for June 2026, adding income potential.
The outlook for XRT is cautiously optimistic, driven by positive retail sales trends and potential Fed easing, but risks include consumer sentiment pressures and inflation. Analyst sentiment is mixed, with some downgrades citing macro headwinds, making it essential to monitor economic indicators for sustained growth.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
